The Place of Cryopreserved Amniotic Membrane (CAM) in Treatment Protocols for Cornea-involved Ocular Surface Disease and Before Refractive Cataract Surgery
Faculty Panelists: Marguerite McDonald, MD; Neel Desai, MD; Clifford Salinger, MD; Mark Milner, MD; John Sheppard, MD
• These 5 renowned experts in anterior segment eye disease and surgery will highlight their recommendations for the use of CAM in the following indications: persistent epithelial defect (PED), corneal ulcer/infectious keratitis, recurrent corneal erosion (RCE), severe dry eye disease (DED), epithelial basement membrane dystrophy (EBMD), neurotrophic keratitis (NK), and optimizing the ocular surface prior to refractive cataract surgery.
• Published in early 2020, this consensus guideline has been developed in order to reexamine the role of cryopreserved amniotic membrane (CAM) in the management of cornea-involved ocular surface diseases and the preparation of the ocular surface for refractive cataract surgery, all of which present continued unmet needs.
• This is an important panel discussion that you don’t want to miss! You will take away how to appropriately incorporate PROKERA into your treatment protocols for common cornea-involved ocular surface diseases.